PURE.US Pure Bioscience Inc
- Market cap
- USD 8.41M
- P/E
- -
- P/B
- 5.57x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jul 2026.
Is PURE.US undervalued?
Graham numberThe Graham number of Pure Bioscience Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pure Bioscience Inc fundamental analysis
No fundamental analysis for Pure Bioscience Inc yet.
Pure Bioscience Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pure Bioscience Inc
PURE Bioscience, Inc. develops and commercializes proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company's technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, includin…
Full company profilePure Bioscience Inc financial statements
Pure Bioscience Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.29M | 1.83M | 1.77M | 1.91M | 6.92M | 3.93M | 1.85M | 1.88M | 1.96M | 2.32M |
| Gross Profit | 848K | 1.07M | 1.01M | 1.18M | 4.02M | 2.08M | 1.00M | 971K | 1.15M | 1.33M |
| Operating Income | 247K | -6.01M | -7.04M | -5.59M | 9.00K | -2.31M | -3.43M | -3.94M | -3.13M | -2.08M |
| EBITDA | -14.1M | -5.99M | -7.15M | -6.31M | 201K | -2.14M | -3.27M | -3.83M | -3.05M | -2.07M |
| Net Income | -21.7M | -6.52M | -7.48M | -6.56M | -6.00K | -2.32M | -3.50M | -3.96M | -3.35M | -2.48M |
| EPS | -0.38 | -0.10 | -0.11 | -0.09 | 0.00 | -0.03 | -0.04 | -0.04 | -0.03 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 7.56M | 3.83M | 2.58M | 1.93M | 6.32M | 4.30M | 4.48M | 1.83M | 818K | 1.19M |
| Total Liabilities | 2.54M | 2.54M | 1.29M | 742K | 1.51M | 970K | 575K | 1.55M | 3.68M | 7.59M |
| Shareholders' Equity | 5.02M | 1.29M | 1.28M | 1.19M | 4.81M | 3.33M | 3.91M | 272K | -2.86M | -6.40M |
| Cash & Short-term Investments | 5.19M | 1.64M | 851K | 398K | 3.84M | 2.39M | 3.39M | 1.10M | 424K | 569K |
| Total Debt | 121K | - | 503K | - | - | 239K | - | 1.02M | 2.95M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.99M | -4.56M | -3.89M | -2.99M | 669K | -1.17M | -2.42M | -3.28M | -2.53M | -1.74M |
| Capital Expenditure | 405K | 226K | 34.0K | 13.0K | 58.0K | 521K | 81.0K | 33.0K | 0.00 | 0.00 |
| Free Cash Flow | -5.40M | -4.79M | -3.92M | -3.00M | 611K | -1.69M | -2.50M | -3.31M | -2.53M | -1.74M |
| Ratios | ||||||||||
| ROE | -431.7% | -505.3% | -583.5% | -551.3% | -0.1% | -69.6% | -89.5% | -1,456.3% | - | - |
| ROA | -286.8% | -170.2% | -290.3% | -339.6% | -0.1% | -53.9% | -78.0% | -217.0% | -409.5% | -208.1% |
| Net Profit Margin | -1,682.3% | -356.0% | -421.4% | -343.7% | -0.1% | -59.1% | -188.7% | -211.0% | -170.7% | -107.1% |
| Debt to Equity | 0.02x | - | 0.39x | - | - | 0.07x | - | 3.75x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pure Bioscience Inc dividends
Pure Bioscience Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:8 on Aug 15, 2012.
Who owns Pure Bioscience Inc
- Insiders 47.56%
- Institutions 0.00%
- Public & others 52.44%
- Shares outstanding 140M
- Free float 73.5M
Pure Bioscience Inc company profile
- Company name
- Pure Bioscience Inc
- Ticker
- PURE.US
- Exchange
- USA Stocks
- Listed since
- Aug 8, 1996
- Sector
- Consumer Defensive
- Industry
- Household Products
- Employees
- 10
- Fiscal year end
- July
- Address
- 771 Jamacha Rd., #512, El Cajon, CA, United States, 92019
- Phone
- 619 596 8600
- Website
- purebio.com
About Pure Bioscience Inc
PURE Bioscience, Inc. develops and commercializes proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company's technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; PURE Hi-Foam Cleaner; and SILVERION, an SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Pure Bioscience Inc management
6- Mr. Mark Stuart ElliottVP of Finance and Principal Financial & Accounting Officer · born 1975
- Mr. Thomas Richard MyersExecutive VP of Technology & Development and Director · born 1952
- Mr. Robert F. BartlettDirector & Advisor · born 1945
- Mr. Jeff KitchellPresident, Corporate Secretary, CEO & Director · born 1971
- Ms. Dolana BlountVice President of Operations & & Regulatory Affairs
- Mr. Tim SteffensmeierVice President of Sales & Marketing